
Genmab's US partner Janssen has received conditional marketing authorization for amivantamab, marketed as Rybrevant, by the EU Commission, Genmab announces in a press release on Monday.
Rybrevant has been approved for patients with advanced non-small cell lung cancer after chemotherapy has failed.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app